ELYRIA, Ohio — Home-health products company Invacare Corp. warned that the looming specter of a federal medical device tax has prompted it to suspend matching 401(k) contributions, stop merit-pay increases for management and freeze hiring.
Invacare also said the tax could lead it to increase prices, shift more production overseas, reduce employee benefits and cut research and development expenditures, according to a regulatory filing. The tax could result in an annual “impact” between $12 million and $14 million to the company.
Invacare has launched an all-out public relations offensive against the potential device tax, in December bringing out the bogeyman that companies often use to scare the public and politicians about the effects of proposed legislation — job cuts.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
It’s entirely possible that Invacare’s threats are more than just political posturing, however. Chief Executive A. Malachi Mixon in December told the Plain Dealer that his firm lost $6.4 million on U.S. sales in 2008 and spent $15 million to $17 million that year on research and development. He said the company’s $38.6 million in earnings that year came entirely from international markets.
Of the company’s approximately 6,100 worldwide employees, about 1,300 are based in Northeast Ohio, a company spokeswoman said.
The House and Senate passed different versions of the tax in their health-overhaul bills. What the tax looks like in its final form, or if it even exists, will be determined when the two chambers iron out the bills’ differences.
The Senate’s version would impose a sales-based tax on device firms that’s intended to raise $2 billion annually beginning in 2011 and $3 billion beginning in 2017. The tax would not be deductible by the manufacturer and the amount of tax payable by a manufacturer would be determined based on market share, Invacare said. The House’s version calls for a smaller tax on device makers.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Invacare said it’s lobbying members of Congress in an effort to make the tax less-onerous to device manufacturers.
Mixon told the Elyria Chronicle-Telegram that he’d like to meet with President Barack Obama when he visits Lorain County on Jan. 22 and ask him to drop the device tax. Mixon made $78,500 in political campaign contributions for the 2008 election cycle to both Democrat and Republican recipients, according to CampaignMoney.com.
Through the first three quarters of 2009, Invacare spent $905,250 lobbying Congress, according to federal records.
In 2008, Invacare reported sales of $1.8 billion. The company expects to issue its 2009 year-end financial information next month.
